Navigation Links
Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
Date:2/12/2013

TEL AVIV, Israel, February 12, 2013 /PRNewswire/ --

Bioassociate has initiated coverage on Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP). The Initiation Report contains a detailed discussion of Oramed's business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks. The Initiation Report is available at: http://www.bioassociate.com/research-and-publications/publications/.

Dr. Ofir Levi , Bioassociate CEO: "Oramed is developing an orally ingestible capsule for the delivery of protein-based therapies with focus on treatment of diabetes. Oramed oral insulin, ORMD-0801, has demonstrated safety and efficacy in several clinical studies, and is scheduled to commence a phase 2 study under IND during 2013. Oramed recently raised $5M in a public offering and moved from being traded on the OTC Market to the NASDAQ. We anticipate that these events jointly with the advancement in the clinical development will increase investors' attention and trading volumes. For these reasons we, at Bioassociate, decide to initiate analysis coverage with a target price of $12.8 per share, which reflects an upside of 38%."

About Bioassociate

Bioassociate is an independent investment research firm specialized in the life-science sector. Bioassociate helps inform readers about small-mid cap life science companies without extensive analyst coverage. Bioassociate structures its teams with multidisciplinary members to conduct specific assignments. The Bioassociate team has industry experience as well as consulting and research track record, providing investors with in-depth scientific insights and their financial manifestation.

Disclosure:

The research report described in this press release is not constructed
'/>"/>

SOURCE Bioassociate
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... more than EUR 1.022 billion in 2013; while production volume reached close to ... leading producing country with a share of 75.5% of the region’s total aluminium ...
(Date:7/28/2015)... -- Deerfield Management Company, L.P. today announced the launch ... invest in groundbreaking advancements in science that may lead ... diseases. The venture capital fund will also back new ... improve the way healthcare is delivered to patients. ... funds in the sector, will donate all profits not ...
(Date:7/28/2015)... July 28, 2015 BioStructures, LLC, a ... hit a milestone of 4,000 implantations of Signafuse® ... cleared in early 2014 as a bone void ... fusion procedures.  This is a distinguished status among ... 6% of new synthetic products have received clearance ...
(Date:7/28/2015)... ZIONA, Israel , July ... (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its ... today announced that Shomrat Shurtz has been appointed ... 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... 25 years of experience in marketing, regulatory and ...
Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) today reported the ... 2009. All dollar amounts referenced herein are in Canadian dollars ... and cash equivalents totaled $7.3 million, compared with $8.6 million ... for the three months ended February 28, 2009 of $1.9 ...
... Wash., April 13 BioLife Solutions, Inc.,(OTC ... marketer of proprietary,cGMP hypothermic storage and cryopreservation ... announced that the Rutgers University ... university-based biologics repository,has adopted the Company,s CryoStor ...
... Cell Biosciences, Inc., a provider of nanoproteomic analysis systems ... a landmark study by a research team from ... Felsher, Associate Professor of Oncology, was senior author on ... serial analysis of oncoprotein activation in clinical samples", appeared ...
Cached Biology Technology:Vasogen Announces First Quarter 2009 Results 2Vasogen Announces First Quarter 2009 Results 3Vasogen Announces First Quarter 2009 Results 4Vasogen Announces First Quarter 2009 Results 5Vasogen Announces First Quarter 2009 Results 6Vasogen Announces First Quarter 2009 Results 7Vasogen Announces First Quarter 2009 Results 8Vasogen Announces First Quarter 2009 Results 9Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media 2Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media 3Cell Biosciences Announces Publication in Nature Medicine 2
(Date:7/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) ... Outlook of the Biometrics Industry 2015 " ... global biometrics market is likely to witness significant ... to the uptake of multiple technologies available. The ... the growth of biometrics in existing applications as ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... department of radiology at Boston University School of Medicine ... Challenges Explorations (GCE) winner, an initiative funded by the ... third year radiology resident at BMC, and Ducksoo Kim, ... the vascular and interventional radiology fellowship at BMC, will ...
... impairment is a transitional stage between normal aging ... this transformation have yet to be studied. Dr. ... Technology, China constructed brain networks using resting-state functional ... (normal controls, patients with early mild cognitive impairment, ...
... with researchers at the University of Quebec at Montreal, ... of pharmaceutical drugs to treat diseases such as cystic ... percentage of pharmaceutical drugs target ion channels, which are ... pivotal role in these serious disorders and that are ...
Cached Biology News:BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 2BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 3New technique for testing drugs to treat cystic fibrosis and epilepsy 2
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Anti-acetyl-Histone H3 (Lys 4) ... sequence ...RT[ Ac K]Q... in which [ ... of human histone H3 ... Molecular Weight: Mr ~17kDa ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
b-Catenin (pSer675), phospho-specific...
Biology Products: